We have chosen a vertebrate model accessible during neurulation, the chick, for analysis of endogenous insulin signaling and its contribution to early embryonic cell survival. Unlike rodents, humans and chickens have a single preproinsulin gene, facilitating its prepancreatic expression characterization. We show that in vivo interference with embryonic insulin signaling using antisense oligonucleotides against the insulin receptor increases apoptosis during neurulation. In contrast, high glucose administration does not increase the level of apoptosis in culture or in vivo. Exogenous insulin and, remarkably, proinsulin achieve similar survival protective effects at 10−8 mol/l. The low abundant preproinsulin mRNA from the prepancreatic embryo is translated to a protein that remains as unprocessed proinsulin. This concurs with the absence of prohormone convertase 2 (PC2) in the embryo, whereas PC2 is present later in embryonic pancreas. A C-peptide–specific antibody stains proinsulin-containing neuroepithelial cells of the chick embryo in early neurulation, as well as other cells in mesoderm- and endoderm-derived structures in the 2.5-day embryo. We have determined by 5′-RACE (rapid amplification of cDNA ends), and confirmed by RNase protection assay, that prepancreatic and pancreatic proinsulin mRNA differ in their first exon, suggesting differential transcriptional regulation. All these data support the role of endogenous proinsulin in cell survival in the chick embryo during important pathophysiologic periods of early development.
Programmed cell death, with the cellular characteristics of apoptosis, is an essential, highly regulated process that occurs during normal embryonic development (1–3). Altered control of cell death is associated with an increasing number of pathologies, including embryonic abnormalities in the nervous system (2–4). We previously showed that balanced insulin signaling is required for normal chick development at early embryonic stages, since blockade with anti-insulin antibodies or an excess of insulin was deleterious to the embryo (5,6). In the chick embryo, before the emergence of pancreas, preproinsulin mRNA levels are developmentally regulated but are not increased by high glucose (7). An increase in apoptosis affecting the neural tube was elicited by preproinsulin mRNA antisense oligonucleotides in chick embryos at day 1.5 of development (equivalent to 3–4 weeks of gestation in humans) (8). Very low or very high prepancreatic insulin availability, due to altered preproinsulin mRNA regulation induced by factors related to or independent of hyperglycemia, may contribute to the appearence of congenital abnormalities.
Low insulin levels were reported to cause retarded growth and development in cultured rat embryos (9), but the inaccessibility of neurulating embryos in mammalian models limits in vivo studies. As an alternative, in the present study, we used the chicken embryo because it is accessible, has a well-established development pattern (10), and is isolated from maternal influences. In addition, as in humans, chickens have only one preproinsulin gene (11), unlike mice and rats, which have two preproinsulin genes (12,13). Here we report the effect of decreased insulin signaling and high glucose conditions on apoptotic cell death in the neurulating chick embryo. We characterize the survival effect of proinsulin relative to various insulins. We also show that the product of preproinsulin mRNA translation in the embryo remains as unprocessed proinsulin and that there are different 5′ leader regions of preproinsulin mRNA in the neurulating embryo compared with the embryonic pancreas.
RESEARCH DESIGN AND METHODS
Fertilized White Leghorn eggs (Granja Rodríguez-Serrano, Salamanca, Spain) were incubated at 38.4°C and 60–90% relative humidity for the indicated periods. The embryos were staged according to Hamburger and Hamilton (HH stages) (14) and referred to by the corresponding day of embryonic development (E).
Whole embryo culture.
E1.5 embryos together with the extraembryonic membranes immobilized by a nitrocellulose ring were cultured as described (7,8). Purified chicken insulin (Litron Lab, Rochester, NY), recombinant human insulin and proinsulin (gifts of Eli Lilly, Indianapolis, IN), or partially purified bovine insulin (Sigma, St. Louis, MO) was added to the culture medium at the indicated doses. Where indicated, the cultured embryos were treated with 38.5 μmol/l oligodeoxynucleotide (ODN) (12.5 nmol total) combined with 25 μg/ml Cytofectin (Glen Research, Sterling, VA) as described (15,16).
All ODNs were synthesized as phosphorothioate derivatives (Oligos Etc., Wilsonville, OR, or Roche Diagnostics, Mannheim, Germany). The antisense to the chicken insulin receptor (AS IR) was 5′-GGTGAACGAATCGGC-3′, and a random sequence of the same base composition (RAN IR) was 5′-GACGGCAGTACGAGT-3′. For glucose treatment, Dulbecco’s modified Eagle’s/F12 medium was replaced by glucose-free RPMI-1640 medium. d-Glucose (Sigma) was added to culture medium at the indicated concentrations.
Detection of apoptosis.
Apoptotic cell death was determined by two methods: counting of pyknotic nuclei in dissociated embryonic cells, performed as described (8,16,17), and terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling (TUNEL) of the fragmented DNA, performed in whole-mount embryos as described (17,18). The two methods provide complementary information. The former allows for a more accurate scoring of the proportion of apoptotic cells, and the latter provides positional information about the location of the dead cells. Our previous reports have shown that both methods reflect the relative differences in cell death among the treatments (8,16–18).
Oligodeoxynucleotide and glucose treatment in vivo.
At the desired incubation time, a lateral window was cut in the eggshell and the developmental stage of the embryos was assessed. When indicated, 12 nmol ODN with 25 μg/ml Cytofectin or 200 μl of 50 mmol/l d- or l-glucose were applied to the embryo. Eggs were sealed with cellotape and incubated further for the indicated period, after which the embryos were processed to quantify apoptotic cell death.
For proinsulin analysis, 100 E1.5-E2 embryos were homogenized, and protein was acid ethanol extracted as described (19). Proteins were fractionated in a Tris-tricine PAGE SDS-14% Prosieve (FMC, Rockland, ME) polyacrylamide reducing gel. For prohormone convertase 2 (PC2) analysis, embryos at E1.5 and pancreata from E13 were homogenized in 50 mmol/l Tris-HCl (pH 7.5), 300 mmol/l NaCl, 10 mmol/l EDTA, 1% (wt/vol) Triton X-100, and protease inhibitor cocktail (Roche). The homogenates were clarified by centrifugation, supernatant protein content was measured, and 80 μg was fractionated in a Tris-tricine PAGE SDS-7.5% gel and transferred to nitrocellulose membranes. These were analyzed for proinsulin by incubation with rabbit anti–C-peptide antibody (Rb40, 1/5,000; generated in our laboratory against synthetic chicken C-peptide ) and reprobed for insulin/proinsulin by incubation with guinea pig anti–porcine insulin/proinsulin antibody (lot HO1P-L; Bio-Teck, Winooski, VT). For PC2, membranes were incubated with rabbit anti-PC2 antibody (1/2,000, “Thumpa”; a gift of C. J. Rhodes, Seattle, WA). All membranes were reprobed with mouse anti–β-tubulin antibody (1/20,000; Sigma) and visualized by chemiluminescence.
Immunostaining was performed on cryosections of E1 and E2.5 embryos by sequential incubation at room temperature with 15% (vol/vol) normal goat serum (30 min), rabbit anti–C-peptide antibody (1/500 dilution ), or rabbit anti–IGF-I antibody (1/500; a gift of Dr. I. Torres-Alemán, Instituto Cajal, Madrid, Spain) for 1 h, biotinylated goat anti–rabbit Ig (1/200; Jackson Immunoresearch Laboratories, West Grove, PA) for 1 h, and Cy2-conjugated streptavidin (1/200; Amersham, Rainham, UK) for 45 min.
Isolation of RNA.
Total RNA was isolated using Trizol reagent (Life Technologies, Gaithersburg, MD) according to the manufacturer’s instructions. Integrity of the RNA was verified by electrophoresis on formaldehyde-agarose gels. PolyA+ RNA was isolated using the Micro-Fast Track kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.
The 5′ rapid amplification of cDNA ends (RACE) procedure was performed according to manufacturer’s instructions (Life Technologies). Briefly, 5 μg total RNA from E1.5 embryos and 1 day postnatal (P1) pancreas were used as templates for a reverse transcriptase reaction with the chicken preproinsulin primer 5′-TTGACTTTCTCGTATTCCT-3′, located in exon 3, 244 bp downstream of the translation start site. The first PCR reaction was carried out with the abridged anchor primer (5′-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3′) and the preproinsulin primer 5′-GACTGCTCACTAGGGGCTGC-3′, located 196 bp downstream of the translation start site, comprising the 3′ and 5′ borders of exons 2 and 3, respectively. A nested PCR was performed on the products of the first PCR reaction using the abridged universal amplification primer (5′-GGCCACGCGTCGACTAGTAC-3′) and the preproinsulin primer 5′-GCTCTCCACACACCAGGTAG-3′, located in exon 2, 136 bp downstream of the translation start site. The PCR products were analyzed in a 2% agarose gel and subcloned into the pCRII-TOPO vector (Invitrogen). Several clones from E1.5 embryos and P1 pancreas were further characterized by sequencing analysis.
Solution hybridization-RNase protection assay.
The preproinsulin exon 1B cDNA probe was generated by subcloning the preproinsulin 5′ RACE product from E1.5 embryos, as described above. A [32P]-labeled antisense riboprobe was generated using T7 polymerase in the presence of CTP, GTP, ATP, and [32P]UTP. The resulting transcripts were purified through a 6-column Bio-Spin (Bio-Rad, Hemel Hempsted, UK). Solution hybridization-RNase protection assay was carried out as described (20), with minor modifications. Either polyA+ or total RNA was hybridized with 2 × 105 cpm of preproinsulin exon 1 antisense riboprobe in a buffer containing 75% formamide (45°C, 16 h). After hybridization, RNA samples were digested with RNase A at 35 μg/ml and RNase T1 at 0.1 units/ml (both from Roche) for 1 h at 30°C. Protected hybrids were extracted with phenol/chloroform, ethanol precipitated, and separated on a 6% polyacrylamide gel containing 7 mol/l urea (Invitrogen). The gel was dried and exposed to film (Biomax MS; Eastman Kodak, Rochester, NY) for 1–8 days.
Blockade of insulin receptor in vivo induces cell death in the neurulating chick embryo.
Insulin prevents apoptotic cell death during chick embryonic development (8,18). To further characterize the tissues and cells dependent on prepancreatic insulin in vivo, we determined the spatial distribution of apoptotic cells in embryos. We blocked the insulin receptor using specific antisense ODN, a strategy that has been successfully employed in the embryo (15,16).
Dead cells found in the neurulating chick embryo (E1.5) were globally scarce (1.4 ± 0.4% of total embryonic cells; see also Morales et al. ). E1.5 embryos treated in ovo with AS IR presented a greater proportion of apoptotic cells (3.8% ± 2.3; n = 6) than did control embryos incubated with RAN IR (1.9% ± 0.9; n = 6, P < 0.025 by Student’s t test). Confocal microscopy analysis of TUNEL-stained whole embryos demonstrated that naturally occurring apoptotic cell death was prevalent along the neural tube, mainly in the anterior region of the prosencephalon and rhombomer 3, as well as in the cochleovestibular ganglia, the somites, and the dorsal lip of the neural tube (Fig. 1A–C). AS IR treatment (Fig. 1D–F) increased the density of apoptotic cell death in locations similar to those observed in untreated or RAN IR–treated embryos (Fig. 1G–I). We did not attempt to block insulin synthesis in the embryo in ovo, as the large volume of the egg provides a significant amount of insulin (21). Nonetheless, both the maternally derived egg insulin and the embryonic product of preproinsulin mRNA can be neutralized with antibodies or antisense ODN, disrupting normal development (5,17).
High glucose has no effect on apoptosis in neurulating chickembryos.
Because hyperglycemia has been associated with diabetic embryopathy in mammals (22–25), we studied whether high glucose increased apoptosis in the neurulating chick embryo. E1.5 embryos were cultured in conditions of low glucose (5.5 mmol/l) or high glucose (50 mmol/l, moderate for the chick embryo surrounded by white, which contains 30 mmol/l glucose ). Culture of the neurulating embryo in growth factor–deprived medium induced time course–dependent apoptosis that was partially attenuated by insulin (8). Glucose had no additional effect on the number of apoptotic cells, independently of the presence or absence of insulin (Fig. 2). As expected, insulin exerted an anti-apoptotic effect in the presence of either glucose concentration. To further confirm the lack of high glucose effect in cell survival during neurulation, E1.5 embryos were treated in ovo. Embryos (n = 16) embedded in 50 mmol/l d-glucose presented a slight, nonsignificant increase in the proportion of apoptotic cells compared with embryos treated with 50 mmol/l l-glucose (a non–metabolically active control) (2.2 ± 1.5% vs. 1.8 ± 0.6%). Altogether, these data suggest that endogenous insulin prevents cell death by additional mechanisms independent of its possible effect on glucose homeostasis.
Exogenous insulin and proinsulin are cell survival–promoting factors in vitro.
We previously showed that proinsulin, the unprocessed insulin precursor, is expressed in the neuroretina (19) and involved in regulating proliferation, differentiation, and cell survival during early retinal development (17,18,27). To investigate whether proinsulin is also active in regulating cell survival during neurulation, we cultured E1.5 embryos in a defined medium in the presence of proinsulin or various insulins at the indicated concentrations. Proinsulin prevented apoptotic cell death with essentially the same potency as chicken insulin (Fig. 3). We used human proinsulin for these treatments; the stimulatory potency of chicken proinsulin may be even higher than that of chicken insulin. In contrast, bovine insulin, the most frequently used in standard culture media, was the least potent in preventing apoptosis in our system.
Endogenous proinsulin remained unprocessed in the neurulating embryo.
To determine whether the endogenous molecule that activated the survival response of the insulin receptor in the embryo was insulin or proinsulin, we performed Western blot analysis with two different antibodies that permit distinction of insulin and proinsulin (19). Immunoblotting of E1.5 extracts with Rb40 (raised against synthetic chicken C-peptide) identified a protein with the electrophoretic mobility of recombinant chicken proinsulin (Fig. 4A, upper panel). There was no cross-reaction with purified chicken insulin, consistent with the antibody specificity. In contrast, a commercial polyclonal anti-insulin antiserum recognized insulin well and proinsulin with much lower affinity (Fig. 4A, bottom panel). Because unprocessed proinsulin is the only “insulin” detectable in embryo extracts, we then studied the expression of the proinsulin-processing convertase PC2 in the neurulating embryo and the mid-embryogenesis pancreas. The 62/63 kDa mature PC2 was found in E13 pancreas, whereas it was not detected in whole E1.5 embryos (Fig. 4B), despite similar β-tubulin levels in both extracts.
Proinsulin is present earlier than IGF-I in the embryo.
The presence of proinsulin in the chick embryo was analyzed by immunohistochemistry in parallel with another member of the insulin family, IGF-I. In gastrulation (E1), proinsulin immunoreactivity was detected mainly in the neuroepithelial cells of the embryonic ectoderm (Fig. 5A and B). Proinsulin staining was also detected in scattered cells within the mesoderm and endoderm layers, coinciding with the proinsulin mRNA expression pattern observed by in situ hybridization studies (8,28). In contrast, IGF-I was not found in any of the three blastoderm layers at this stage (Fig. 5F). In early organogenesis (E2.5), proinsulin immunostaining was also detected in the three embryonic layers (Fig. 5D and E). Among the ectodermal structures, proinsulin was more prevalent in the dorsal ectoderm, covering the neural tube and in the floor plate. Some mesodermal structures such as the notochord, dermamyotome, nephric tube, and nephrogenic mesenchyme showed positive proinsulin immunostaining. The prospective digestive endoderm was also positive. IGF-I displayed a very restricted staining pattern; at this caudal level, it was detected in only a few ectodermic cells, as well as in the prospective digestive endoderm (Fig. 5G). At the level of the rostral somites, IGF-I was strongly positive in sympathetic and dorsal root ganglia (data not shown), and in the head, it was positive in cranial ganglia (Fig. 5H), among other structures. A negative control with preimmune rabbit immunoglobulins showed no immunostaining (data not shown).
Prepancreatic and pancreatic preproinsulin mRNAs differ in their 5′-leader sequences.
In previous studies, we demonstrated that preproinsulin mRNA levels are differentially regulated by glucose in embryonic pancreas and the neurulating embryo (7). Whereas glucose increases preproinsulin mRNA expression in E13 pancreas, it has no effect in E1.5 embryo preproinsulin mRNA levels. One mechanism by which to achieve developmental and tissue-specific differential gene expression regulation is to generate alternative transcripts. To characterize possible 5′-heterogeneity in the chicken preproinsulin mRNA, we used the 5′-RACE method, a sensitive procedure for amplifying and cloning the 5′ end of a specific mRNA, on RNA isolated from E1.5 embryos or P1 pancreas. A ∼300-bp initial PCR product was obtained in pancreas (Fig. 6A). The level of preproinsulin mRNA expression in E1.5 embryo was below detection limits by ethidium bromide staining. The subsequent nested PCR displayed a ∼240-bp product in pancreas and a ∼280-bp product in E1.5 embryos. Cloning and sequencing analysis of these PCR products revealed two different 5′-untranslated exon 1 sequences in the pancreatic and E1.5 embryo preproinsulin mRNAs (now termed exon 1A and 1B, respectively). Exon 1A contained 57 nucleotides, and exon1B comprised the complete exon 1A plus 32 nucleotides at the 5′ end (Fig. 6B). Interestingly, both exons 1A and 1B differed from that predicted by Perler et al. (11) based on genomic cloning (see discussion). We confirmed the presence of each preproinsulin mRNA variant by RNase protection assay with a riboprobe generated using the 5′-RACE product from E1.5 embryos as a template. This probe is complementary to exon1B and to 153 nucleotides of exon 2 (Fig. 7A), rendering a 210-bp protected band for pancreas and a 242-bp band for E1.5 (Fig. 7B). These results suggest that the preproinsulin gene has different transcriptional regulation in the neurulating embryo than in the pancreas. The alternative first exon, which is untranslated in both cases, does not change the primary protein product, preproinsulin.
Recent studies have demonstrated the involvement of disregulated cell death in the genesis of the diabetic embryopathy (22–25,29), a nonsurprising finding given the essential role of programmed cell death in embryonic development (1–3). High glucose levels induce apoptotic cell death in the mouse preimplantation embryo (24,29) and during neurulation (25). In addition, the levels of a novel gene, dep-1, which is regulated by the transcription factor Pax-3, are reduced in the diabetic embryopathy of the mouse (30). Nonetheless, it is likely that congenital malformations, including neural tube defects, are multifactorial processes (31,32) in which maternal hyperglycemia is an important, but not exclusive, etiology. The use of a nonmammalian model to analyze insulin action during neurulation may help to identify processes that eventually can be of importance for mammals as well. One should also consider that there are differences even between mice and humans concerning insulin action–related genes. Whereas the knockout mice for the insulin receptor present only a slight reduction of embryonic size, the spontaneous leprechaun human dwarfs show a more extreme phenotype (33). Another recent example is the basal normoglycemia of the sulfonylurea receptor 1 (SUR1) knockout mouse, strikingly different from the persistent hyperinsulinemia/hypoglycemia of infants who lack SUR1 action (34).
There are strong data supporting the role of prepancreatic insulin in cell survival during development in the maternally independent chick embryo model. During gastrulation and neurulation, the chick embryo is avascular and prepancreatic. Remarkably, it expresses preproinsulin mRNA, and the insulin receptor is functional at these stages, as indicated by its tyrosine kinase activity and anti-apoptotic effect, features shared in part by other species (8,28,35–38). Interference in vivo with insulin receptor synthesis using antisense oligodeoxynucleotides increases apoptosis in the neurulating embryo, demonstrating the physiological relevance of insulin signaling in the regulation of embryonic cell survival/death (this study and Morales et al. ). Here, we show that exogenous proinsulin is nearly as effective as insulin in preventing the increase in cell death caused by culture with growth factor deprivation, and this concurs with the observation that the product present in the embryo is proinsulin. Accordingly, we also show the absence of PC2 expression in the neurulating embryo. Both PC2 and PC3 function in the pancreatic regulated secretory pathway and are required for efficient proinsulin processing (39,40), which is essential for the postnatal demands of metabolic regulation. Because young embryos usually lack typical endocrine granules (41), proinsulin in the neurulating chick embryo is probably secreted by a constitutive secretory pathway. In the neuroretina cultured in hormone-free medium, we have observed that proinsulin secretion to the medium is rapid (27). The location of the proinsulin-producing cells in the embryo is consistent with its proposed role in neuroepithelial cell survival. During E1, scattered neuroepithelial cells are immunostained; when the neural tube is closed, at E2.5, some ectodermal cells on its dorsal side are still proinsulin-positive. This pattern is quite different from that of IGF-I, expressed later, and from that of IGF-II (not shown). Altogether, these observations are reminiscent of features in the chick embryo retina, another organ in which the anti-apoptotic role of proinsulin/insulin is relevant (17,18). In this tissue, embryonic proinsulin signals through low discriminating hybrid insulin-IGF receptors (42). Proinsulin not only has high affinity for the hybrid receptors (42) but also a slower dissociation rate than insulin (43), and signal duration may be important for the survival effect. A similar receptor study has not yet been possible due to the scarce tissue of the neurulating embryo. Although the mechanisms implicated in the protective anti-apoptotic effect of proinsulin remain to be studied in detail, we have proposed that the maintenance of chaperone heat shock cognate 70 (Hsc70) levels during neurulation is at least part of them (16). We anticipate that the antioxidant function of insulin may also be implicated. Insulin treatment prevents the increase in oxidative stress caused by diabetes (44). Insulin may also counteract the tumor necrosis factor (TNF)-α malformations increase linked to diabetic embryopathy (45) and help restore the inositol metabolism disturbed by the hyperglycemia (46) in rat models of embryopathy.
An additional important piece of evidence on an alternative growth-related role for embryonic proinsulin/insulin is the characterization that the 5′ untranslated region (UTR) of the early embryo preproinsulin mRNA contains a longer sequence than the pancreas mRNA, suggesting differential transcriptional and/or postrancriptional control of these alternative transcripts. The alternative exon 1A or 1B corresponding to the 5′UTR does not alter the amino acid sequence of either prepancreatic or pancreatic proinsulin. Surprisingly, none of these exons coincides with the previously predicted exon 1 based on the genomic sequence of the chicken preproinsulin 5′-flanking region (11). Thus far, only a partial chicken cDNA from pancreas had been reported (47). Moreover, we did not find the exon 1A or 1B sequences within the ∼600 bp of the chicken 5′-flanking genomic preproinsulin provided by Soares et al. (48), suggesting that both exons are located upstream from this region. Further experiments will be required to address whether the two preproinsulin transcripts originate from the use of different transcription start sites under the control of a unique promoter or from the presence of two alternative promoters. The use of multiple and developmental-specific promoters or transcription start sites provides a flexible mechanism for developmental stage–specific regulation of individual regions by environmental signals and has been extensively described for both IGF-I and IGF-II (49). Indeed, we previously showed that preproinsulin mRNA did not change in response to glucose in the neurulating embryo, whereas preproinsulin mRNA from embryonic pancreas increased twofold (7). Analysis of the promoter sequences from the chicken preproinsulin gene should allow us to better understand how early embryonic cells regulate the expression of locally required proinsulin before the emergence of the pancreas. The alternative 5′ ends of the preproinsulin transcript may additionally confer differential stability or translatability of the mRNA.
The data presented here emphasize the impact of low insulin signaling independently of the deleterious effect of high glucose in the chick embryo model, as it develops in a 30 mmol/l glucose environment, and increasing this to 50 mmol/l glucose does not augment apoptosis. Embryos at a slightly earlier stage, nevertheless, display relatively high glucose metabolism rates (50), and after E2, high glucose is teratogenic, as indeed is very high insulin (6). Our results suggest that endogenous proinsulin prevents cell death, during a critical neurulation stage, by mechanisms other than its metabolic effect on glucose homeostasis.
This study was funded by grants PM99-0094 to E.J.d.l.R., PB97-0143 from the Dirección General de Investigación y Desarrollo (Spain), and 8.6/0030/2000 from the Comunidad Autónoma de Madrid to F.d.P. The fellowships to E.R. and J.S. were awarded by the Ministerio de Educación y Cultura. C.H.-S. is a Ramón y Cajal Fellow from the Ministerio de Ciencia y Tecnología (Spain).
We thank V. Quesada for technical assistance and A. Mansilla for useful comments on the results and manuscript. We also thank Eli Lilly for providing recombinant human insulin and proinsulin and Dr. I. Torres-Alemán for the anti–IGF-I antibody.
Address correspondence and reprint requests to Flora de Pablo, Group of Growth Factors in Vertebrate Development, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Velázquez 144, E-28006 Madrid, Spain. E-mail: firstname.lastname@example.org.
Received for publication 2 July 2001 and accepted in revised form 28 November 2001.
C.H.-S. and E.R. contributed equally to this work.
AS, antisense; E, day of embryonic development; IR, insulin receptor; ODN, oligodeoxynucleotide; P, day of postnatal development; PC2, prohormone convertase 2; RACE, rapid amplification of cDNA ends; RAN, random; SUR1, sulfonylurea receptor 1; TUNEL, terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling; UTR, untranslated region.